In this issue of the journal, Schulz and colleagues present new data describing one-year outcomes from the ISAR-REACT 4 trial.
This study recruited patients undergoing PCI in the setting of a non-ST-elevation, acute coronary syndrome presentation. Subjects were randomised to two different periprocedural antithrombotic regimes: bivalirudin or combination therapy with unfractionated heparin (UFH) and abciximab. The reported rates of death, non-fatal myocardial infarction and target vessel revascularisation are near identical.
It is interesting to note that an increased risk of bleeding, observed at 30 days1, in patients receiving abciximab therapy, did not result in differences in key outcome measures at ...
Special issue on PCR Valves e-Course; patient-centring the Heart Team, COVID and clinical trials...
Optimising the delivery of self-expanding valves according to vascular access
November 20, 2020